Highlights
The study reported a clinical complete response (cCR) rate of 39% (95% CI 25-54) in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or declined cisplatin-based chemotherapy.
No grade 4 or higher treatment-related adverse events occurred, with grade 3 events limited to 16% of the cohort, primarily diarrhea.
